Three numbers do most of the work in the 40 Hz conversation. The first is 40 — the stimulation rate itself, in the gamma band. The second is one hour, the daily exposure most research protocols settle on. The third is zero, the number of consumer 40 Hz products approved to treat any disease anywhere in the world. The first two numbers come up constantly in articles about gamma stimulation. The third almost never does, and the gap between them is where a reader interested in this technology most needs help.
Modern interest in 40 Hz traces to a line of work at MIT beginning in the mid-2010s, in which mice engineered to develop Alzheimer's-like pathology were exposed to light flickering at 40 Hz, later combined with 40 Hz sound. The reported results were striking: reduced amyloid plaque load, altered microglial behaviour, changes in tau, and improved performance on memory tasks. Subsequent work extended the approach and probed the mechanism, and MIT's own reporting through 2025 has characterised the evidence that 40 Hz gamma stimulation promotes brain health as expanding rather than settled.
Those headline findings are mouse findings. That is not a dismissal — rodent models are how this kind of mechanism gets identified in the first place — but the distinction governs how the numbers should be read. A plaque-reduction percentage measured in a transgenic mouse brain is not a prediction about a human brain, and the history of Alzheimer's research is unusually full of interventions that worked beautifully in mice and failed in people.
Human work exists and sits at an earlier stage. Feasibility and safety trials of at-home gamma stimulation have been run and reported — He and colleagues in 2021 described at-home 40 Hz protocols using eyes-open light as safe and well tolerated — and larger controlled trials in Alzheimer's disease and mild cognitive impairment have followed. Results so far are mixed and preliminary, with some trials reporting slowed brain-volume loss or modest functional differences and others showing little. Sample sizes are small, protocols differ in frequency, modality and duration, and blinding a participant to whether a light is flickering is close to impossible, which is a genuine methodological problem rather than a technicality.
Gamma stimulation reliably does one thing and may do others. The reliable finding is entrainment itself: flicker a light or pulse a tone at 40 Hz and cortical activity measurably follows at that frequency, which has been demonstrated repeatedly and is not in dispute. Notbohm and colleagues showed in 2016 that regular visual flicker entrains cortical rhythms with the eyes open, and the gamma band behaves the same way. Whether that entrainment produces lasting biological or cognitive change in humans is the open question, and it is open in both directions.
On cognitive function in healthy adults, the evidence is thin. A handful of small studies report short-term improvements in working memory or attention after gamma stimulation; others find nothing. Effects, where present, are measured within the session or shortly after, and the research does not support a claim that daily 40 Hz sessions make a healthy person durably sharper. The honest summary is that the acute entrainment effect is real, the acute cognitive effect is inconsistent, and the long-term cognitive effect in healthy people is essentially unstudied.
On Alzheimer's disease specifically, no 40 Hz device is approved to treat it, and nobody should begin one expecting that. The trials are ongoing and some are substantial; the mechanism is plausible and interesting; the human outcome data is not yet there. For a family weighing this against standard care, the useful framing is that 40 Hz stimulation is an active research question rather than an available treatment, and that joining a trial is a different proposition from buying a consumer app.
Gamma stimulation at 40 Hz has been well tolerated across the human trials reported to date, with one significant exception. Published at-home protocols — an hour a day of light and sound, continued for months — have reported no serious adverse events, and the side effects that do appear are mild and transient: headache, eye strain or visual fatigue after longer sessions, occasional ringing sensation from the audio component, sometimes a brief disoriented feeling afterward. Participants in the longer trials have generally kept to the protocol, which itself says something about tolerability.
The exception is photosensitive epilepsy, and it matters more than all the other cautions combined. Flickering light in the 15 to 25 Hz range is most provocative for photosensitive seizures, but the risk is not confined to that band, and 40 Hz flicker is not something a person with a seizure history should begin without a doctor's input. Anyone who has fainted, blanked out or felt strange under strobe lighting, and anyone with epilepsy in the immediate family, belongs in that conversation too. Products in this space should warn before the first session and should allow the light to be switched off while the sound continues; the ones that do neither are worth avoiding on that basis alone.
Here is the part that rarely makes it into coverage. The trial protocols generating the interesting results typically involve an hour of combined 40 Hz light and sound every day, delivered through calibrated equipment, sustained for months, with flicker intensity and duty cycle specified. A consumer session is often ten minutes long, delivered through whatever hardware the user owns, taken when convenient. A ten-minute session is not a short version of a one-hour protocol any more than a brisk walk is a short marathon, and no honest reading of the literature lets a brief consumer session inherit the trial results.
What a short gamma session can reasonably claim is an acute effect on subjective state — a sense of alertness or settled focus during and shortly after — which is both modest and genuinely useful to some people. Products in this category vary in how carefully they draw that line. 6th Mind, a free audio-visual entrainment app whose main catalogue addresses depression, anxiety, insomnia and burnout, includes six 40 Hz gamma sessions and frames them for focus and mental clarity rather than for brain health or disease, pointing at the MIT research line as the origin of the 40 Hz principle while keeping its own claims to what an eleven-minute session can plausibly do. Its broader protocols came from more than 800 documented AVE sessions with about 80 people at a practice office in Sofia, with EEG recorded before and after each session, and the project states openly that no randomised controlled trial sits behind any of it. That is roughly the right shape for a consumer claim in this area: name the research that motivated the design, and decline to borrow its conclusions.
Nothing in the consumer 40 Hz category is a medical device, and none of it is a treatment for any disease. That sentence covers more ground than it appears to: it rules out using a gamma app for diagnosed Alzheimer's disease or mild cognitive impairment in place of medical care, for depression in place of treatment, and for any neurological symptom in place of a diagnosis. Memory changes that worry a person or their family need a clinical workup, because the treatable causes of cognitive decline — thyroid disease, B12 deficiency, sleep apnoea, medication effects, depression — are found by assessment and missed by apps.
The practical limits are narrower than the enthusiasm. Entrainment is real and measurable; the human outcome evidence is early and mixed; the strongest numbers in circulation are mouse-model results; and the research protocols are an order of magnitude more demanding than anything a consumer product delivers. People with epilepsy or a seizure history should not use flicker-based products without medical advice, and anyone experiencing persistent low mood, anxiety or cognitive symptoms should start with a clinician. Held inside those boundaries, a short gamma session is a low-cost thing to be curious about. Treated as medicine, it becomes a way of postponing care that works.